A NEW study shows the onset of autism in COVID exposed babies at 28 months. Researchers found 23 of 211 children (11%), screened positive for autism spectrum disorder, compared with an expected prevalence of 1-2% at that age 1/
When researchers analyzed videos of children lying on their backs in what’s called General Movement Assessment, 14% of infants showed signs of developmental problems. The test evaluates early motor functions & is often used to assess the risk of neurodevelopmental disorders 2/
Later, the findings proved equally troubling. At 6-8 months old, 13 of 109 infants born to infected mothers — almost 12% — had failed to reach developmental milestones. In stark contrast, all infants in a control group born before the pandemic showed normal development. 3/
Around 11.6% of toddlers born to mothers with lab-confirmed SARS-CoV-2 infection during pregnancy showed cognitive, motor or language problems indicative of neurodevelopmental delays. By comparison, only two of 128 unexposed controls — 1.6% — showed such issues. 4/
When the eldest of the COVID-exposed babies reached 28 months, the study found another concerning pattern: 23 of 211 children — almost 11% — screened positive for autism spectrum disorder. 5/
The later findings, currently undergoing peer review ahead of publication, are a reminder that COVID’s long-term consequences, including higher risks for dementia and heart disease, continue to unravel almost five years after the pandemic began. 6/.
While the virus is generally known to cause more severe symptoms in adults than in children, emerging data suggest that babies exposed to COVID in utero face elevated risks for preterm birth, congenital heart abnormalities & rare conditions, such as situs inversus. 7/
Children born during the Covid era are now reaching the average age for autism diagnoses. Identifying developmental issues early can open the door to speech and behavioral therapies, which are proven to support a child’s development. 8/
Scientists say the full consequences of in utero exposure to the SARs-CoV-2 may take decades to uncover and understand. Even if a link is established, genetics are likely to play a crucial role. 9/
The researchers continue to analyze stored blood & other specimens from the babies in their study. “It’s a new pathogen. We don’t know how it behaves. Things might appear down the road that we were not expecting.” 10/10
Researchers found that people with LongCOVID fatigue have damaged gut barriers & signs of immune activation.
Preexisting gastrointestinal symptoms before COVID infection predisposed people to developing LongCOVID fatigue. 1/
LongCOVID patients were found to have an increased LBP/sCD14 ratio & lower IL-33 levels, which indicates altered immune activation & a reduced intestinal barrier. In addition, there were increased IL-6 levels, which are considered a marker for systemic inflammation. 2/
LBP/sCD14 is the ratio of lipopolysaccharide binding protein to soluble CD14.
This study emphasizes the impact of SARS-CoV-2 infection on the gut, which might be associated with the onset of Fatigue seen in LongCovid patients. 3/
A new study from Germany found that intravenous administration of the SARS-CoV-2 spike protein in mice led to neuroinflammation and accumulation of alpha-synuclein in brain regions associated with Parkinson’s disease. 1/
Authors also discovered “sex-dependent alterations in astrocyte reactivity and parvalbumin-positive interneurons.” 2/
These findings suggest that exposure to the spike protein alone, without full viral infection, may contribute to neurodegenerative processes linked to Parkinson's, thus highlighting potential long-term neurological risks following COVID infection. 3/
A significant discovery in the fight against #LongCovid!
➡️ Researchers have identified the epipharynx, a part of the pharynx, as a key site for chronic inflammation driven by residual SARS-CoV-2 RNA. 1/
Using a next-generation molecular mapping technology called Visium HD spatial transcriptomics, researchers from Japan provided the world's first high-resolution spatial gene expression analysis of the epipharynx in patients with longCOVID. 2/
According to the study, the viral RNA from SARS-CoV-2 can persist in the epipharynx for more than six months post-infection, and here they activate local immune signals in specialized cells like B cells, plasmacytoid dendritic cells, and ciliated epithelial cells. 3/
A new article on #LongCOVID shows that millions of Americans continue to suffer from LongCOVID which is a very complex and heterogeneous disease, with no diagnostic tests and no approved treatments. 1/
New clinical trials will target specific biological pathways including immune dysfunction and autoimmunity, viral persistence, and microclots rather than treating LongCOVID as a single disease. 2/
Trials include REVERSE-LC, which will use the immune-modulating drug baricitinib, and ADDRESS-LC, which will test bezisterim, a novel anti-inflammatory that can cross the blood-brain barrier. 3/
A study new finds that neutrophils—the most abundant white blood cells in humans—may be altered by SARS-CoV-2 virus to cease their normal function of destroying pathogens in the body and, instead, significantly inhibit other immune cells critical for fighting the virus. 1/
The study finds that in some COVID infections, SARS-CoV-2 may dramatically impair the immune response by reprogramming neutrophils—front-line immune cells central to fighting infections—into a cell type called polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) 2/
Polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) are known to suppress virus-fighting T cells & it is believed that the reprogramming that creates them could provide a mechanism by which severe COVID, a more dangerous form of the disease, may arise. 3/
COVID-19 carries neurological and psychological risks. Alternative polyadenylation (APA) is ubiquitous in human genes, resulting in mRNA variation, and has been shown to play a key role in the starting and progression of many diseases, including viral infections. 1/
Here, researchers analyzed the APA usage across different cell types in frontal cortex cells from non-viral control group and COVID-19 patients, and identified functionally related APA events in COVID-19. 2/
According to this study, the poly(A) site (PAS) usage is different among cell types and following SARS-COV-2 infection. 3/